The topical treatment of anthroponotic cutaneous leishmaniasis with the tincture of thioxolone plus benzoxonium chloride (Thio-Ben) along with cryotherapy: A single-blind randomized clinical trial

Dermatologic Therapy

Volumn 28, Issue 3, 2015, Pages 140-146

  Daie Parizi, Mohammad Hossein ^a   Karvar, Mehran ^b   Sharifi, Iraj ^c   Bahrampour, Abbas ^a   Heshmat Khah, Amireh ^a   Rahnama, Zahra ^d   Baziar, Zahra ^b   Amiri, Rezvan ^d  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anthroponotic cutaneous leishmaniasis; Thio Ben; topical treatment

Indexed keywords

BENZOXONIUM CHLORIDE; LIQUID NITROGEN; MEGLUMINE ANTIMONATE; TIOXOLONE; ANTIPROTOZOAL AGENT; BENZALKONIUM; DRUG COMBINATION; LACTONE; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND; TOPICAL ANTIINFECTIVE AGENT;

ADULT; ALLERGIC REACTION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYOTHERAPY; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; OUTCOME ASSESSMENT; PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; TINCTURE; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; CHILD; DRUG ADMINISTRATION; DRUG COMBINATION; IRAN; LEISHMANIASIS, CUTANEOUS; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; PARASITOLOGY; PATIENT COMPLIANCE; PRESCHOOL CHILD; RECURRENT DISEASE; REMISSION; SINGLE BLIND PROCEDURE; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; ANTIPROTOZOAL AGENTS; BENZALKONIUM COMPOUNDS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRYOTHERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; IRAN; LACTONES; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MOLECULAR SEQUENCE DATA; ORGANOMETALLIC COMPOUNDS; PATIENT COMPLIANCE; RECURRENCE; REMISSION INDUCTION; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930758822     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12229     Document Type: Article

References (17)

1. Goto H, Lindoso JA,. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010: 8: 419-433.
2. World Health Organization (WHO). Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. Geneva: WHO; 2010. WHO technical report series; no. 949.
3. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M,. WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012: 7: e35671.
4. Desjeux P,. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004: 27: 305-318.
5. Singh S, Sivakumar R,. Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 2004: 10: 307-315.
6. World Health Organization. Essential leishmaniasis maps. WHO/NTD/IDM HIV/AIDS, Tuberculosis and Malaria (HTM) World Health Organization, October 2010. http://www.who.int/leishmaniasis/leishmaniasis-maps/en/. Accessed October 1, 2014.
7. Nadim A, Seyedi-Rashti MA,. Brief review of the epidemiology of various types of leishmaniasis in Iran. Acta Med Iran 1971: 14: 99-106.
8. Sharifi I, Fekri AR, Aflatonian A, Nadim A, Nikian Y, Kamesipour A,. Cutaneous leishmaniasis in primary school children in the Southeastern Iranian city of Bam, 1994-95. Bull World Health Organ 1998: 76: 289-293.
9. Sharifi F, Sharifi I, Zarean M, Parizi MH, Aflatoonian M, Harandi MF, Zahmatkesh R, Mashayekhi M, Kermanizadeh A,. Spatial distribution and molecular identification of leishmania species from endemic foci of South Eastern Iran. Iran J Parasitol 2012: 7: 45-52.
10. Masmoudi A, Hariz W, Marrekchi S, Amouri M, Turki H,. Old world cutaneous leishmaniasis: diagnosis and treatment. J Dermatol Case Rep 2013: 7: 31-41.
11. Markle WH, Makhoul KH,. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician 2004: 69: 1455-1460.
12. Alavi-Naini R, Fazaeli A, O'Dempsey T,. Topical treatment modalities for old world cutaneous leishmaniasis: a review. Prague Med Rep 2012: 113: 105-118.
13. González U, Pinart M, Reveiz L, Alvar J,. Interventions for old world cutaneous leishmaniasis. Cochrane Database Syst Rev 2008 Oct 8;(4): CD005067.
14. Esfandiarpour I, Alavi A,. Evaluating the efficacy of allopurinol and meglumine antimoniate (glucantime) in the treatment of cutaneous leishmaniasis. Int J Dermatol 2002: 41: 521-524.
15. Al-Qubati Y, Janniger EJ, Schwartz RA,. Old world cutaneous leishmaniasis: cryosurgery using carbon dioxide slush in a resource-poor country. Int J Dermatol 2012: 51: 1217-1220.
16. Daie Parizi MH,. Treatment of cutaneous leishmaniasis with local application of the tincture of Thioxolone and benzoxonium chloride (first research in the world) at annual congress of Iranian society of pediatrics, Tehran, Iran, Oct. 1992. The annual book of congress, pp 121-125, 1992.
17. Daie Parizi MH, Shamsaddini S,. Comparison between topical treatment with Thioxolone, benzoxonium chloride tincture and intralesional injection of Meglumine Antimoniate on cutaneous Leishmaniasis. J Kerman Univ Med Sci 1996: 3: 7-14.